WO2021224924A1 - Esters d'acide cannabidiolique pour le traitement de la détresse respiratoire, dont le syndrome de détresse respiratoire aiguë et le coronavirus - Google Patents

Esters d'acide cannabidiolique pour le traitement de la détresse respiratoire, dont le syndrome de détresse respiratoire aiguë et le coronavirus Download PDF

Info

Publication number
WO2021224924A1
WO2021224924A1 PCT/IL2021/050518 IL2021050518W WO2021224924A1 WO 2021224924 A1 WO2021224924 A1 WO 2021224924A1 IL 2021050518 W IL2021050518 W IL 2021050518W WO 2021224924 A1 WO2021224924 A1 WO 2021224924A1
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutical composition
use according
group
cannabinoid
thc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IL2021/050518
Other languages
English (en)
Inventor
Anat IOSUB-AMIR
Peter James WELBURN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Webb Cynthia
Epm Ip Inc
Original Assignee
Webb Cynthia
Epm Ip Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Webb Cynthia, Epm Ip Inc filed Critical Webb Cynthia
Publication of WO2021224924A1 publication Critical patent/WO2021224924A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Definitions

  • the present invention relates to compositions and methods for treating respiratory distress including acute respiratory distress syndrome and coronavirus.
  • the present invention relates to pharmaceutical compositions and formulations comprising a cannabidiolic acid (CBDA) ester alone or in combination with one or more additional cannabinoid compound(s), for use in treating respiratory inflammation including acute respiratory distress syndrome and coronavirus.
  • CBDA cannabidiolic acid
  • Respiratory Inflammation or inflammation in the lung is usually caused by pathogens, such as viruses and bacteria, or by exposure to toxins, pollutants, irritants, and allergens.
  • the inflammation can also be a result of genetic disorders, e.g., Alpha-1 antitrypsin (AAT) deficiency that causes COPD (chronic obstructive pulmonary disease).
  • AAT Alpha-1 antitrypsin
  • the inflammation is initiated by stimuli at the epithelial surface, and cells already present in the tissue mediate acute inflammation. The stimuli activate the resident leukocytes and structural cells to produce various cytokines, chemokines, and growth factors that cause inflammatory symptoms.
  • ARDS acute respiratory distress syndrome
  • COPD chronic obstructive pulmonary disease
  • Coronaviruses are the largest group of viruses belonging to the Nidovirales order, which includes Coronaviridae, Arteriviridae, and Roniviridae families.
  • the Coronavirinae comprise one of two subfamilies in the Coronaviridae family, with the other being the Torovirinae.
  • Coronaviruses are associated with illness from the common cold to more severe conditions such as Severe Acute Respiratory Syndrome (SARS-CoV) and Middle East Respiratory Syndrome (MERS-CoV).
  • Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the positive-sense, single- stranded RNA coronavirus that causes the coronavirus disease 2019 (COVID-19).
  • Coronaviruses are zoonotic, meaning they are transmitted between animals and people. Common signs of coronavirus infection include respiratory symptoms, fever, coughing, shortness of breath and breathing difficulties. High concentrations of cytokines were recorded in plasma of critically ill patients infected with COVID-19. In more severe cases, infection can cause pneumonia, respiratory inflammation, severe acute respiratory syndrome, kidney failure and death.
  • CBD Cannabidiol
  • CBD cannabidiolic acid
  • CBDA-ME is a relatively unknown cannabinoid and remains understudied and its effects are only just starting to become clear.
  • CBDA-ME is a stable derivative of CBDA and can be pharmacological active in vivo.
  • WO 2018/235079 discloses compositions comprising CBDA esters and uses thereof in the treatment of a condition, disease or symptom associated with 5-HT IA receptors.
  • WO 2020/186010 discloses pharmaceutical compositions including a cannabinoid acid ester compound alone or in combination with one or more additional cannabinoid compounds.
  • the PCT application discloses the uses of the pharmaceutical compositions in treating a variety of diseases including joint disease, skin disease, gastrointestinal disease, uterine-related disorder, Non-Alcoholic Fatty Liver Disease (NAFLD), chronic kidney disease (CDK), diabetes dyslipidemia, metabolic syndrome, hyperglycemia, obesity and reducing or maintaining cholesterol levels or lowering LDL/HDL ratio.
  • Vuolo et al. disclose that CBD reduces airway inflammation and fibrosis in experimental allergic asthma (European Journal of Pharmacology 843 (2019) 251- 259).
  • the present invention provides pharmaceutical compositions comprising a cannabinoid, wherein the cannabinoid component comprises a cannabidiolic acid (CBDA) ester alone or in combination with one or more additional cannabinoid compound(s), and a pharmaceutically acceptable carrier, excipient or diluent, for treating respiratory distress including acute respiratory distress syndrome and coronavirus.
  • the respiratory distress is caused by coronavirus.
  • the respiratory distress is acute respiratory distress syndrome (ARDS).
  • the respiratory inflammation is asthma or chronic obstructive pulmonary disease (COPD).
  • the cannabinoid component comprises CBDA ester in combination with one or more extract of a cannabis plant, and a pharmaceutically acceptable carrier, excipient or diluent.
  • the CBDA esters are more active in treating coronavirus and respiratory inflammation than either CBDA or CBD.
  • the compositions comprising CBDA esters exhibit a prolonged and significant therapeutic effect in respiratory inflammation. Without wishing to be bound by any particular theory or mechanism of action, the therapeutic effect of the composition may be due to the stability of the CBDA ester.
  • the significant anti-inflammatory effect of CBDA-ME reduces the coronavirus impact on lungs at the critical stage of infection and therefore, enables the body to recover and deal effectively with the respiratory distress.
  • the present invention provides a pharmaceutical composition
  • a cannabinoid component comprising a cannabidiolic acid (CBDA) ester represented by the structure of Formula (I) alone or in combination with one or more additional cannabinoid compound(s), and a pharmaceutically acceptable carrier, excipient or diluent, for use in treating respiratory distress or inflammation
  • Ri and R2 are each independently selected from the group consisting of a linear or branched, unsubstituted or substituted C 1 -C 15 alkyl, a linear or branched, unsubstituted or substituted C 2 -C 15 alkenyl, and a linear or branched, unsubstituted or substituted C 2 -C 15 alkynyl; and stereoisomers and salts thereof.
  • Ri is methyl.
  • the cannabidiolic acid ester is cannabidiolic acid methyl ester (CBDA-ME).
  • the CBDA ester in the compositions of the present invention is represented by the formula (la):
  • the CBDA ester in the compositions of the present invention is represented by the formula (lb):
  • the CBDA ester is designated HU-580 (also denoted herein EPM301):
  • the respiratory distress is caused by a virus.
  • the respiratory distress is caused by coronavirus.
  • the coronavirus is selected from the group consisting of Severe Acute Respiratory Syndrome (SARS-CoV), Middle East Respiratory Syndrome (MERS-CoV), and severe acute respiratory syndrome coronavirus 2 (SARS- CoV-2).
  • SARS-CoV Severe Acute Respiratory Syndrome
  • MERS-CoV Middle East Respiratory Syndrome
  • SARS- CoV-2 severe acute respiratory syndrome coronavirus 2
  • the coronavirus is COVID-19.
  • the respiratory distress is acute respiratory distress syndrome (ARDS).
  • ARDS acute respiratory distress syndrome
  • the additional cannabinoid compound is selected from the group consisting of cannabidiol (CBD), cannabigerol (CBG), D 8 - tetrahydrocannabinol (A S -THC), A 9 -tetrahydrocannabinol (A 9 -THC), cannabinol (CBN), A 9 (ll)-tetrahydrocannabinol (exo-THC), cannabichromene (CBC), tetrahydrocannabinol-C3 (THC-C3), tetrahydrocannabinol-C4 (THC-C4), tetrahydrocannabinol-C7 (THC-C7), esters thereof and combination thereof.
  • CBD cannabidiol
  • CBG cannabigerol
  • a S -THC D 8 - tetrahydrocannabinol
  • a 9 -THC cannabinol
  • CBN can
  • the one or more additional cannabinoid compound(s) are present in one or more extracts of a cannabis plant.
  • the cannabis plant extract is obtained from a strain selected from the group consisting of Cannabis sativa, Cannabis indica, Cannabis ruderalis, a hybrid strain, and combinations thereof.
  • the cannabis plant extract is obtained from a strain selected from the group consisting of a high-CBD strain, a high-THC strain, and a combination thereof.
  • the cannabis plant extract comprises at least one cannabinoid selected from the group consisting of cannabidiol (CBD), tetrahydrocannabinol (THC), cannabinol (CBN), cannabigerol (CBG), cannabichromene (CBC), acids thereof and combinations thereof.
  • the cannabis plant extract comprises about 1% (w/w) of CBD. According to some embodiments, the cannabis plant extract comprises about 10% (w/w) of CBD. According to some embodiments, the cannabis plant extract comprises about 25% (w/w) of CBD.
  • the cannabis plant extract comprises about 1% (w/w) of THC. According to some embodiments, the cannabis plant extract comprises about 10% (w/w) of THC. According to some embodiments, the cannabis plant extract comprises about 25% (w/w) of THC.
  • the cannabis plant extract is formed through contact with a suitable solvent or a combination of solvents.
  • the solvent is selected from the group consisting of a polar solvent, a hydrocarbon solvent, carbon dioxide, and combinations thereof.
  • the cannabinoid component can be emulsified, dissolved, dispersed or encapsulated in formulations suitable for use in either aqueous based or oil-based carriers.
  • the present pharmaceutical composition is in the form of an emulsion, solution or dispersion. Each possibility represents a separate embodiment.
  • the present pharmaceutical composition may include an aqueous based or an oil-based carrier. Each possibility represents a separate embodiment.
  • the pharmaceutical composition is formulated for inhalation.
  • the pharmaceutical composition is a dry powder formulation.
  • the pharmaceutical composition is formulated for an administration via vaporization.
  • the pharmaceutical composition is formulated into a dosage form suitable for intranasal, oral, intravenous, intraarterial, or subcutaneous administration.
  • a dosage form suitable for intranasal, oral, intravenous, intraarterial, or subcutaneous administration.
  • Each embodiment represents a separate embodiment of the invention.
  • the pharmaceutical composition is formulated for an oral administration.
  • the pharmaceutical composition is a non- aqueous composition. According to some embodiments, the pharmaceutical composition is formulated in a form of a powder. According to some embodiments, the pharmaceutical composition is powder suitable for multi-dose reservoir dry powder inhaler (DPI).
  • DPI multi-dose reservoir dry powder inhaler
  • the pharmaceutical composition is a liquid composition.
  • the pharmaceutical composition is formulated as a capsule, a tablet, a liquid, or a syrup.
  • the dosage form is granules or pellets delivered in a solution, a suspension or filled into a capsule or compressed into a tablet.
  • the pharmaceutical composition further comprises triglycerides, fats, lipids, oils, fatty acids, solvents or mixtures thereof.
  • the pharmaceutical composition comprises an edible oil selected from the group consisting of copaiba oil, coconut oil, cottonseed oil, soybean oil, safflower oil, sesame oil, sunflower oil, castor oil, corn oil, olive oil, palm oil, peanut oil, and poppy seed oil.
  • the pharmaceutical composition comprises an alcohol and a second solvent.
  • the alcohol is ethanol.
  • the second solvent is polyethylene glycol (PEG) or propylene glycol.
  • the pharmaceutical composition is formulated for slow release of the CBDA ester.
  • the pharmaceutical composition further comprises a release retarding agent or a mixture of release retarding agents.
  • the pharmaceutical composition is at least partly coated by an enteric-coating agent.
  • the CBDA ester is provided in microencapsulation particles. According to certain embodiments, the CBDA ester is provided in liposomal capsule particles.
  • the pharmaceutical composition comprises phospholipid(s).
  • the pharmaceutical composition comprises a phospholipid selected from the group consisting of naturally occurring phospholipids and synthetic phospholipids.
  • the naturally occurring phospholipid is selected from the group consisting of soy lecithin, egg lecithin, hydrogenated soy lecithin, hydrogenated egg lecithin, and a combination thereof.
  • the synthetic phospholipid is selected from the group consisting of phosphocholines, phosphoethanolamines, phosphatidic acids, phosphoglycerols, phosphoserines, mixed chain phospholipids, lysophospholipids, pegylated phospholipids, and a combination thereof. Each possibility represents a separate embodiment of the invention.
  • the phospholipid may form micelles, emulsions or liposomes.
  • the pharmaceutical composition comprises cyclodextrins.
  • the cyclodextrin is selected from the group consisting of hydroxypropyl b-cyclodextrin, sulfobutylether b-cyclodextrin, and methyl ⁇ -cyclodextrin (Mbq ⁇ ) and a combination thereof.
  • the excipient is selected from the group consisting of emulsifiers, buffering agents, pH adjusting agents, preservatives, antioxidants, stabilizers, and a combination thereof. Each possibility represents a separate embodiment of the invention.
  • the pharmaceutical composition further comprises vitamins, anti-oxidants, minerals, and/or flavoring agents.
  • the composition comprises less than about 10% (w/w) of the cannabinoid component. According to additional embodiments, the composition comprising less than about 7% (w/w) of the cannabinoid component. According to further embodiments, the composition comprising less than about 5% (w/w) of the cannabinoid component. According to yet further embodiments, the composition comprising less than about 2% (w/w) of the cannabinoid component. According to some embodiments, the composition comprising less than about 1% (w/w) of the cannabinoid component. According to additional embodiments, the composition comprising less than about 0.5% (w/w) of the cannabinoid component.
  • the pharmaceutical composition comprises a unit dosage form of at least about 20 mg of CBDA ester or a mixture of cannabinoids comprising CBDA ester.
  • the dosage form comprises about 20 mg to about 2,000 mg of CBDA ester or a mixture of cannabinoids comprising CBDA ester.
  • the dosage form comprises about 20 mg to about 500 mg of CBDA ester.
  • the dosage form comprises about 50 mg to about 1,000 mg of CBDA ester.
  • the dosage form comprises about 200 mg to about 1,000 mg of CBDA ester.
  • the dosage form comprises about 50 mg, 100 mg, about 200 mg, about 300 mg, about 400 mg, about 500 mg, about 600, about 700 mg, about 800 mg, about 900 mg, or about 1000 mg of CBDA ester or a mixture of cannabinoids comprising CBDA ester.
  • composition described herein can be administered with one or more other therapeutic agents.
  • the pharmaceutical composition further comprises an anti-inflammatory drug.
  • the pharmaceutical composition further comprises corticosteroid(s).
  • the pharmaceutical composition further comprises an antibiotic drug.
  • the respiratory inflammation is acute respiratory inflammation.
  • the respiratory inflammation is chronic respiratory inflammation.
  • the respiratory inflammation is pneumonitis.
  • the respiratory inflammation is asthma.
  • the respiratory inflammation is COPD.
  • the respiratory inflammation is caused by a condition selected from the group consisting of asthma, chronic obstructive pulmonary disease (COPD), pneumonia and eosinophilic bronchitis, airways viral infection, airways bacterial infection, fungal infection, airways parasite infection, pulmonary vasculitis, pulmonary sarcoidosis, inflammation and/or infection associated with lung transplantation, acute lung graft rejection or bronchiolitis obliterans syndrome (BOS), pulmonary artery hypertension (PAH), bronchitis, chronic bronchitis, sinusitis, cystic fibrosis (CF), primary ciliary dyskinesia (PCD), alveolar proteinosis, idiopathic pulmonary fibrosis (IPF), eosinophilic acute respiratory distress syndrome (ARDS), mechanical ventilation-associated inflammation and/or infection, silicosis, chemical agent-related airway disease, and any combination thereof.
  • COPD chronic obstructive pulmonary disease
  • COPD chronic obstruct
  • the respiratory inflammation is caused by a pathogen.
  • the respiratory inflammation is caused by a pathogen selected from the group consisting of viruses, bacteria, parasites and fungi.
  • the present invention provides a method for treating or preventing respiratory distress or inflammation comprising administering to a subject in need of such treatment a therapeutically effective amount of the pharmaceutical composition described herein.
  • the method is for treating coronavirus. According to additional embodiments, the method is for treating acute respiratory distress syndrome.
  • the pharmaceutical composition is administered through inhalation from a vaporizer or metered dose inhaler. According to other embodiments, the pharmaceutical composition is administered orally.
  • the pharmaceutical composition is administered once a day, once a week, once in two weeks, once in three weeks or once a month.
  • the subject is a mammal. According to certain embodiments, the subject is a human subject. According to some embodiments, the pharmaceutical composition is used in combination with other therapeutic agents for treatment or prevention of respiratory inflammation.
  • the method further comprises administering an anti-inflammatory agent.
  • the method further comprises administering corticosteroids.
  • the method comprises administering an additional non-steroidal anti-inflammatory drug.
  • the method further comprises administering an antibiotic drug.
  • the treatment decreases respiratory inflammation in said patient compared to said patient prior to treatment with CBDA ester.
  • the pharmaceutical composition is administered through inhalation from a vaporizer or metered dose inhaler. According to other embodiments, the pharmaceutical composition is administered orally.
  • the pharmaceutical composition is administered once a day, once a week, once in two weeks, once in three weeks or once a month.
  • the subject is a mammal. According to certain embodiments, the subject is a human subject.
  • the pharmaceutical composition is used in combination with other therapeutic agents for treatment or prevention of respiratory inflammation.
  • the method further comprises administering an anti-inflammatory agent.
  • the method further comprises administering corticosteroids.
  • the method comprises administering an additional non-steroidal anti-inflammatory drug.
  • the method further comprises administering an antibiotic drug.
  • the treatment decreases respiratory inflammation in said patient compared to said patient prior to treatment with CBDA ester.
  • the present invention provides methods of treating respiratory inflammation including coronavirus and acute respiratory distress syndrome (ARDS), comprising administering to a subject in need thereof a therapeutic effective amount of a cannabidiolic acid (CBDA) ester alone or in combination with one or more additional cannabinoid compound(s), and a pharmaceutically acceptable carrier, excipient or diluent.
  • ARDS acute respiratory distress syndrome
  • Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), formerly known as the 2019 novel coronavirus (2019-nCoV), is a positive-sense single- stranded RNA virus. It is contagious among humans and is the cause of coronavirus disease 2019 (COVID-19). There is no vaccine, but several antiviral drugs are already in clinical trials.
  • SARS-CoV-2 has strong genetic similarity to known bat coronaviruses, making a zoonotic origin in bats likely, although an intermediate reservoir such as a pangolin is thought to be involved. From a taxonomic perspective SARS-CoV-2 is classified as a strain of the species severe acute respiratory syndrome-related coronavirus. SARS- CoV-2 is the cause of the ongoing 2019-20 coronavirus outbreak.
  • the highly stable compounds of the present invention allow prolonged biological activities for treating respiratory inflammation.
  • cannabinoid used in this description, claims, and other conjugations is used to mean any compound that interacts with a cannabinoid receptor.
  • Ligands for these receptor proteins include the endocannabinoids (produced naturally in the body by humans and animals), the phytocannabinoids (found in cannabis and some other plants), and synthetic cannabinoids (manufactured artificially).
  • cannabinoid acid refers to the acid form of the above-mentioned cannabinoids.
  • Suitable cannabinoids include but are not limited to certain tetrahydropyran analogs: A s -tetrahydrocannabinol, A 9 -tetrahydrocannabinol (THC), cannabinol (CBN), cannabidiol (CBD), cannabigerol (CBG), A y ( 1 1 (-tetrahydrocannabinol (exo-THC), cannabichromene (CBC), tetrahydrocannabinol-C3 (THC-C3), tetrahydrocannabinol- C4 (THC-C4), tetrahydrocannabinol-C7 (THC-C7), their salts, solvates, metabolites, and metabolic precursors.
  • THC cannabinopyran analogs
  • THC cannabinol
  • CBD cannabinol
  • CBD cannabidiol
  • CBD cannabigerol
  • CBD cannabidiol
  • cannabidiol refers to CBD.
  • CBD is obtained from industrial hemp extract with a trace amount of THC or from cannabis extract using high CBD cannabis cultivars.
  • cannabidiol may be obtained from plant extract, or may be prepared synthetically (manufactured artificially).
  • CBD cannabidiolic acid
  • CBDA cannabidiolic acid ester
  • CBDA-ME cannabidiolic acid methyl ester
  • the compounds provided herein may contain one or more chiral centers. Such chiral centers may each be of either of the ( R ) or (S) configuration. In case a compound of the invention contains more than one chiral center, each one of those chiral centers may be of the ( R ) or (S) configuration, independently. Thus, the compounds provided herein may be enantiomerically pure, or be stereoisomeric or diastereomeric mixtures.
  • the present invention provides a pharmaceutical composition
  • a cannabinoid comprising a cannabinoid
  • the cannabinoid component comprises a cannabidiolic acid (CBDA) ester represented by the structure of Formula (I) alone or in combination with one or more additional cannabinoid compound(s), and a pharmaceutically acceptable carrier, excipient or diluent, for use in treating or preventing respiratory inflammation or distress, Formula (I) wherein
  • CBDA cannabidiolic acid
  • Ri and R 2 are each independently selected from the group consisting of a linear or branched, unsubstituted or substituted C 1 -C 15 alkyl, a linear or branched, unsubstituted or substituted C 2 -C 15 alkenyl, and a linear or branched, unsubstituted or substituted C 2 -C 15 alkynyl; and stereoisomers and salts thereof.
  • the present invention provides a pharmaceutical composition
  • a cannabinoid comprising a cannabinoid
  • the cannabinoid component comprises a cannabidiolic acid (CBDA) ester represented by the structure of Formula (I) alone or in combination with one or more additional cannabinoid compound(s), and a pharmaceutically acceptable carrier, excipient or diluent, for use in treating or preventing respiratory inflammation or distress,
  • CBDA cannabidiolic acid
  • Ri and R 2 are each independently selected from the group consisting of a linear or branched C 1 -C 15 alkyl unsubstituted or substituted by one or more groups selected from the group consisting of hydroxyl, halogen, amino, thiol, and phosphate, a linear or branched C 2 -C 15 alkenyl unsubstituted or substituted by one or more groups selected from the group consisting of hydroxyl, halogen, amino, thiol, and phosphate, and a linear or branched C 2 -C 15 alkynyl unsubstituted or substituted by one or more groups selected from the group consisting of hydroxyl, halogen, amino, thiol, and phosphate; and stereoisomers and salts thereof.
  • the respiratory distress is caused by coronavirus.
  • the respiratory distress is acute respiratory distress syndrome (ARDS).
  • the present invention provides a pharmaceutical composition
  • a cannabinoid comprising a cannabinoid
  • the cannabinoid component comprises a cannabidiolic acid (CBDA) ester represented by the structure of Formula (I) alone or in combination with one or more additional cannabinoid compound(s), and a pharmaceutically acceptable carrier, excipient or diluent, for use in treating coronavirus, wherein
  • CBDA cannabidiolic acid
  • Ri and R 2 are each independently selected from the group consisting of a linear or branched, unsubstituted or substituted C 1 -C 15 alkyl, a linear or branched, unsubstituted or substituted C 2 -C 15 alkenyl, and a linear or branched, unsubstituted or substituted C 2 -C 15 alkynyl; and stereoisomers and salts thereof.
  • the present invention provides a pharmaceutical composition
  • a cannabinoid wherein the cannabinoid component comprises a cannabidiolic acid (CBDA) ester represented by the structure of Formula (I) alone or in combination with one or more additional cannabinoid compound(s), and a pharmaceutically acceptable carrier, excipient or diluent, for use in treating or preventing coronavirus
  • Ri and R 2 are each independently selected from the group consisting of a linear or branched C 1 -C 15 alkyl unsubstituted or substituted by one or more groups selected from the group consisting of hydroxyl, halogen, amino, thiol, and phosphate, a linear or branched C 2 -C 15 alkenyl unsubstituted or substituted by one or more groups selected from the group consisting of hydroxyl, halogen, amino, thiol, and phosphate, and a linear or branched C 2 -C 15 alkyny
  • the one or more additional cannabinoid compound(s) are present in one or more extracts of a cannabis plant.
  • Ri is a linear or branched, substituted or unsubstituted C 1 -C 15 alkyl. According to some embodiments, Ri is a linear or branched, substituted or unsubstituted C 1 -C 10 alkyl. According to some embodiments, Ri is a linear or branched, substituted or unsubstituted C 5 -C 10 alkyl. According to some embodiments, Ri is a linear or branched, substituted or unsubstituted C 5 -C 15 alkyl. According to some embodiments, Ri is a linear or branched, substituted or unsubstituted C 2 -C 15 alkenyl.
  • Ri is a linear or branched, substituted or unsubstituted C 2 -C 10 alkenyl. According to some embodiments, Ri is a linear or branched, substituted or unsubstituted C 5 -C 10 alkenyl. According to some embodiments, Ri is a linear or branched, substituted or unsubstituted C 5 -C 15 alkenyl. According to some embodiments, Ri is a linear or branched, substituted or unsubstituted C 2 -C 15 alkynyl. According to some embodiments, Ri is a linear or branched, substituted or unsubstituted C 2 -C 10 alkynyl.
  • Ri is a linear or branched, substituted or unsubstituted C 5 -C 10 alkynyl. According to some embodiments, Ri is a linear or branched, substituted or unsubstituted C 5 -C 15 alkynyl.
  • Ri is a linear substituted C 1 -C 15 alkyl. According to some embodiments, Ri is a linear unsubstituted C 1 -C 15 alkyl. According to some embodiments, Ri is a branched substituted C 3 -C 15 alkyl. According to some embodiments, Ri is a branched unsubstituted C 3 -C 15 alkyl.
  • Ri is a linear substituted C 2 -C 15 alkenyl. According to some embodiments, Ri is a linear unsubstituted C 2 -C 15 alkenyl. According to some embodiments, Ri is a branched substituted C 3 -C 15 alkenyl. According to some embodiments, Ri is a branched unsubstituted C 3 -C 15 alkenyl.
  • Ri is a linear substituted C 2 -C 15 alkynyl. According to some embodiments, Ri is a linear unsubstituted C 2 -C 15 alkynyl. According to some embodiments, Ri is a branched substituted C 4 -C 15 alkynyl. According to some embodiments, Ri is a branched unsubstituted C 4 -C 15 alkynyl.
  • Ri is unsubstituted. According to some embodiments, Ri is a linear unsubstituted C 1 -C 10 alkyl. According to some embodiments, Ri is a linear unsubstituted C 1 -C 6 alkyl. According to some embodiments, Ri is a linear unsubstituted C 1 -C 4 alkyl. According to some embodiments, Ri is methyl or ethyl. According to some embodiments, Ri is methyl.
  • R 2 is a linear or branched, substituted or unsubstituted C 1 -C 15 alkyl. According to some embodiments, R 2 is a linear or branched, substituted or unsubstituted C 1 -C 10 alkyl. According to some embodiments, R 2 is a linear or branched, substituted or unsubstituted C 5 -C 10 alkyl. According to some embodiments, R 2 is a linear or branched, substituted or unsubstituted C 5 -C 15 alkyl. According to some embodiments, R 2 is a linear or branched, substituted or unsubstituted C 2 -C 15 alkenyl.
  • R 2 is a linear or branched, substituted or unsubstituted C 2 -C 10 alkenyl. According to some embodiments, R 2 is a linear or branched, substituted or unsubstituted C 5 -C 10 alkenyl. According to some embodiments, R 2 is a linear or branched, substituted or unsubstituted C 5 -C 15 alkenyl. According to some embodiments, R 2 is a linear or branched, substituted or unsubstituted C 2 -C 15 alkynyl. According to some embodiments, R 2 is a linear or branched, substituted or unsubstituted C 2 -C 10 alkynyl.
  • R 2 is a linear or branched, substituted or unsubstituted C 5 -C 10 alkynyl. According to some embodiments, R 2 is a linear or branched, substituted or unsubstituted C 5 -C 15 alkynyl.
  • R 2 is a linear substituted C 1 -C 15 alkyl. According to some embodiments, R 2 is a linear unsubstituted C 1 -C 15 alkyl. According to some embodiments, R 2 is a branched substituted C 3 -C 15 alkyl. According to some embodiments, R 2 is a branched unsubstituted C 3 -C 15 alkyl.
  • R 2 is a linear substituted C 2 -C 15 alkenyl. According to some embodiments, R 2 is a linear unsubstituted C 2 -C 15 alkenyl. According to some embodiments, R 2 is a branched substituted C 3 -C 15 alkenyl. According to some embodiments, R 2 is a branched unsubstituted C 3 -C 15 alkenyl.
  • R 2 is a linear substituted C 2 -C 15 alkynyl. According to some embodiments, R 2 is a linear unsubstituted C 2 -C 15 alkynyl. According to some embodiments, R 2 is a branched substituted C 4 -C 15 alkynyl. According to some embodiments, R 2 is a branched unsubstituted C 4 -C 15 alkynyl.
  • R 2 is a linear unsubstituted C 1 -C 6 alkyl. According to some embodiments, R 2 is a linear unsubstituted C 1 -C 4 alkyl. According to some embodiments, R 2 is C 5 H 11 .
  • the CBDA ester in the compositions of the present invention is represented by the formula (la):
  • the CBDA ester in the compositions of the present invention is represented by the formula (lb):
  • the CBDA ester is designated EPM301:
  • alkyl refers to a saturated aliphatic hydrocarbon, including straight- chain or linear-chain, branched-chain and cyclic alkyl groups.
  • the alkyl group has 1-15 carbons designated here as C 1 -C 15 alkyl.
  • the alkyl group has 2-6 carbons designated here as C2-C6-alkyl.
  • the alkyl group has 2-4 carbons designated here as C2-C4-alkyl.
  • the alkyl group may be unsubstituted or substituted by one or more groups selected from the group consisting of hydroxyl, halogen, amino, thiol, phosphate, and combinations thereof.
  • halo and halogen refer to the fluoro, chloro, bromo or iodo atoms. There can be one or more halogens, which are the same or different.
  • alkenyl refers to an aliphatic hydrocarbon group containing at least one carbon-carbon double bond including straight-chain or linear-chain, branched- chain and cyclic alkenyl groups.
  • the alkenyl group has 2-15 carbon atoms (a C2-15 alkenyl).
  • the alkenyl group has 2-4 carbon atoms in the chain (a C2-4 alkenyl).
  • alkenyl groups include, but are not limited to, ethenyl, propenyl, n-butenyl, i-butenyl, 3-methylbut-2-enyl, n-pentenyl, heptenyl, octenyl, cyclohexyl-butenyl and decenyl.
  • An alkylalkenyl is an alkyl group as defined herein bonded to an alkenyl group as defined herein.
  • the alkenyl group can be unsubstituted or substituted through available carbon atoms with one or more groups defined hereinabove for alkyl.
  • alkynyl refers to an aliphatic hydrocarbon group containing at least one carbon-carbon triple bond including straight-chain and branched-chain.
  • the alkynyl group has 2-15 carbon atoms in the chain (a C2-15 alkynyl).
  • the alkynyl group has 2-4 carbon atoms in the chain (a C2-4 alkynyl).
  • Exemplary alkynyl groups include, but are not limited to, ethynyl, propynyl, n-butynyl, 2-butynyl, 3-methylbutynyl, n-pentynyl, heptynyl, octynyl and decynyl.
  • alkylalkynyl is an alkyl group as defined herein bonded to an alkynyl group as defined herein.
  • the alkynyl group can be unsubstituted or substituted through available carbon atoms with one or more groups defined hereinabove for alkyl.
  • the additional cannabinoid compound is selected from the group consisting of cannabidiol (CBD), cannabigerol (CBG), D 8 - tetrahydrocannabinol (A S -THC), A 9 -tetrahydrocannabinol (A 9 -THC), cannabinol (CBN), A 9 (ll)-tetrahydrocannabinol (exo-THC), cannabichromene (CBC), tetrahydrocannabinol-C3 (THC-C3), tetrahydrocannabinol-C4 (THC-C4), tetrahydrocannabinol-C7 (THC-C7), esters thereof and combination thereof.
  • CBD cannabidiol
  • CBG cannabigerol
  • a S -THC D 8 - tetrahydrocannabinol
  • a 9 -THC cannabinol
  • CBN can
  • the CBDA ester of Formula (I) or the cannabinoid compound includes any solvate thereof.
  • solvate refers to a physical association of a compound disclosed herein with one or more solvent molecules. This physical association involves varying degrees of ionic and covalent bonding, including hydrogen bonding. In certain instances, the solvate will be capable of isolation. “Solvate” encompasses both solution-phase and isolatable solvates. Non limiting examples of suitable solvates include ethanolates, methanolates and the like. A “hydrate” is a solvate in which the solvent molecule is water.
  • the present disclosure also includes any polymorph thereof.
  • polymorph refers to a particular crystalline or amorphous state of a substance, which can be characterized by particular physical properties such as X-ray diffraction, electron diffraction, IR spectra, Raman spectra, melting point, and the like.
  • cannabinoids disclosed herein can be prepared by any manner known to those skilled in the art.
  • it may be isolated or extracted from a natural source or prepared by synthetic or semi- synthetic means.
  • cannabinoids can be isolated by extraction from cannabis plants. Plants in the cannabis genus include, but are not limited to, Cannabis sativa, Cannabis indica, and Cannabis ruderalis. Each possibility represents a separate embodiment. These plants are the natural sources of cannabinoids.
  • certain cannabinoids are isolated or extracted from cannabis plants and then derivatized to the CBDA ester of Formula (I). It is, however, to be understood by the skilled in the art that some of the cannabinoid esters of Formula (I) do not occur in nature, and therefore chemical synthesis is required for their production.
  • extract refers a product prepared by extraction by physical means (e.g. by comminuting, pressing, heating, pulsed electric field assisted treatments, shear treatments and pressure wave treatments), by chemical means (e.g. by treatment with an acid, a base and/or a solvent) and/or by biochemical means.
  • the term refers to a liquid substance obtained through extraction from a given substance, or to a concentrate or essence which is free of, or substantially free of solvent.
  • extract may be a single extract obtained from a particular extraction step or series of extraction steps. Extract also may be a combination of extracts obtained from separate extraction steps or separate feedstocks. Such combined extracts are thus also encompassed by the term “extract”.
  • the extract may be obtained from any part of the plant e.g. from leaves, flowers, stems, roots, fruits and seeds.
  • the extract may be aqueous or oily.
  • the cannabis plant extract is formed with a suitable solvent or a combination of solvents.
  • the solvent is selected from the group consisting of a polar solvent, a hydrocarbon solvent, carbon dioxide, and a combination thereof.
  • the cannabis plant extract is produced by a process, which comprises contacting the cannabis plant material with a suitable solvent or a combination of solvents.
  • the process further comprises isolating a fraction soluble in said solvent.
  • the process further comprises removing the solvent from the soluble fraction, to acquire the extract.
  • Suitable solvents include but not limited to water, ethanol, ethyl acetate, CO 2 , methanol, acetone, and acetic acid.
  • Suitable polar solvents include polar organic solvent(s), including, but not limited to halogenated hydrocarbons (e.g. chloroform, dichloromethane), ethers (e.g. diethyl ether, tetrahydrofuran), alcohols (e.g. ethanol, methanol, isopropanol), esters (e.g. ethyl acetate), nitriles (e.g. acetonitrile), sulfones and sulfoxides (e.g.
  • halogenated hydrocarbons e.g. chloroform, dichloromethane
  • ethers e.g. diethyl ether, tetrahydrofuran
  • alcohols e.g. ethanol, methanol, isopropanol
  • esters
  • Suitable non-polar solvents include hydrocarbons, including but not limited to aliphatic hydrocarbons (e.g. hexane, pentane, heptane, petroleum ether) and/or aromatic hydrocarbons (e.g. benzene, toluene).
  • the solvent is ethanol.
  • the solvent comprises ethanol, such as aqueous ethanol.
  • the extraction is by CO 2 .
  • extract refers to a liquid or semi-solid or resinous substance obtained through extraction from plants defined in the present application, i.e. extracts obtained from cannabis plant e.g. Cannabis sativa, Cannabis indica, and Cannabis ruderalis.
  • the term refers to a mixture of liquid or semi-solid, resinous substances obtained through extraction from two or more different plants.
  • the term refers also to a compound purified from the extract.
  • extract has the meaning of a mixture or combination of two or more extracts.
  • cannabisbis extract refers to one or more plant extracts from the cannabis plant.
  • a cannabis extract contains, in addition to one or more cannabinoids, one or more non-cannabinoid components which are co-extracted with the cannabinoids from the plant material. Their respective ranges in weight will vary according to the starting plant material and the extraction methodology used.
  • Cannabinoid-containing plant extracts may be obtained by various means of extraction of cannabis plant material. Such means include but are not limited to supercritical or subcritical extraction with CO2, extraction with hot or cold gas and extraction with solvents.
  • the term refers to a mixture of liquid or semi-solid, resinous substances obtained through extraction from two or more different cannabis species.
  • the term refers also to a compound purified from the extract.
  • cannabis plant is a CBD-rich strain of cannabis plant or THC-rich strain of cannabis plant. Each possibility represents a separate embodiment.
  • the cannabis plant extract is obtained from a strain selected from the group consisting of Cannabis sativa, Cannabis indica, Cannabis ruderalis, a hybrid strain, a high-CBD strain, a high-THC strain, and a combination thereof.
  • the cannabis plant extract comprises at least one cannabinoid selected from the group consisting of cannabidiol (CBD), tetrahydrocannabinol (THC), cannabinol (CBN), cannabigerol (CBG), cannabichromene (CBC), acids thereof and combination thereof.
  • the cannabis plant extract comprises about 1% (w/w) of CBD. According to some embodiments, the cannabis plant extract comprises about 10% (w/w) of CBD. According to some embodiments, the cannabis plant extract comprises about 25% (w/w) of CBD. According to some embodiments, the cannabis plant extract comprises about 45% (w/w) of CBD.
  • the cannabis plant extract comprises about 1% (w/w) of THC. According to some embodiments, the cannabis plant extract comprises about 10% (w/w) of THC. According to some embodiments, the cannabis plant extract comprises about 25% (w/w) of THC. According to some embodiments, the cannabis plant extract comprises about 45% (w/w) of THC.
  • hybrid strain refers to different strains of Cannabis which include differing amounts and/or ratios of the various cannabinoid compounds.
  • Cannabis sativa typically has a relatively high THC/CBD ratio.
  • Cannabis indica has a relative low THC/CBD ratio compared to Cannabis sativa (although the absolute amount of THC can be higher in Cannabis indica than in Cannabis sativa).
  • high-CBD strain and CBD-rich strain are directed to a strain of cannabis plant which comprises CBD and optionally one or more additional cannabinoids, such as, for example, but not limited to: THC, CBN, and the like.
  • CBD is the main component in the high-CBD strain.
  • high-THC strain and “THC -rich strain” are directed to a strain of cannabis plant which comprises THC and optionally one or more additional cannabinoids, such as, for example, but not limited to: CBD, CBN, and the like.
  • THC is the main component in the high-THC strain.
  • the cannabinoid component combination of the present invention is generally prepared by conventional methods such as are known in the art of making a mixture with the ratio described above. Such methods typically involve mixing of the CBDA ester and one or more additional cannabinoid compound(s), or one or more extract of a cannabis plant in one or more steps to a relatively uniform state, with or without heating, cooling, application of vacuum, and the like.
  • compositions disclosed herein may be administered locally or systemically.
  • the pharmaceutical composition is formulated for inhalation.
  • the pharmaceutical composition is a non-aqueous composition.
  • the pharmaceutical composition is a dry powder formulation.
  • the pharmaceutical composition is formulated for an administration via vaporization.
  • the pharmaceutical composition is powder suitable for multi-dose reservoir dry powder inhaler (DPI).
  • DPI dry powder inhaler
  • dry powder refers to a composition that contains respirable dry particles that are capable of being dispersed in an inhalation device and subsequently inhaled by a subject. Such a dry powder may contain no more than about 25%, no more than about 20%, or no more than about 15% water or other solvent, or be substantially free of water or other solvent, or be anhydrous.
  • the powders described herein may contain one or more metal cation salts, which can be monovalent metal cation salts, divalent metal cation salts, or combinations thereof.
  • Salts suitable for use in the dry powders include, for example, a sodium salt, a potassium salt, a lithium salt and any combination thereof.
  • the dry particles are highly dispersible, and can be delivered to the respiratory tract of a patient using a passive DPI solely relying on the patient's own breathing pattern.
  • the delivery of the respirable dry particles to the respiratory tract is relatively independent of patient's inspiratory flowrate, meaning that the delivered dose is very similar for patients breathing in at a relatively high or low flow rates.
  • the respirable dry particles described herein can include a physiologically or pharmaceutically acceptable excipient.
  • a pharmaceutically-acceptable excipient includes any of the standard carbohydrates, sugar alcohols, and amino acids that are known in the art to be useful excipients for inhalation therapy, either alone or in any desired combination. These excipients are generally relatively free-flowing particulates, do not thicken or polymerize upon contact with water, are toxicologically innocuous when inhaled as a dispersed powder and do not significantly interact with the therapeutic agent in a manner that adversely affects the desired physiological action.
  • Carbohydrate excipients that are useful in this regard include the mono- and polysaccharides.
  • Representative monosaccharides include carbohydrate excipients such as dextrose (anhydrous and the monohydrate; also referred to as glucose and glucose monohydrate), galactose, mannitol, D-mannose, sorbose and the like.
  • Representative disaccharides include lactose, maltose, sucrose, trehalose and the like.
  • Representative trisaccharides include raffinose and the like.
  • Other carbohydrate excipients include maltodextrin and cyclodextrins.
  • Representative sugar alcohols include mannitol, sorbitol and the like.
  • the excipient may be present in an amount less than about 90%, in an amount less than about 80%, in an amount less than about 70%, in an amount less than about 60%, in an amount less than about 50%, in an amount less than about 40%, in an amount less than about 35%, in an amount less than about 30%, in an amount less than about 25%, in an amount less than about 20%, in an amount less than about 17%, in an amount less than about 15%, in an amount less than about 12%, in an amount less than about 10%, in an amount less than about 8%, in an amount less than about 6%, in an amount less than about 5%, in an amount less than about 4%, in an amount less than about 3%, in an amount less than about 2%, or in an amount less than about 1%, all percentages are by weight of the dry particles.
  • the dry particles contain an excipient selected from leucine, maltodextrin, mannitol and any combination thereof.
  • the excipient is leucine, maltodextrin, or mannitol.
  • the pharmaceutical composition is formulated for inhalation, comprising propellant.
  • propellants include inhalation acceptable hydrofluoroalkanes (HFAs). These include, but are not limited to, HFA 134a (tetrafluoroethane) HFA 227 (heptafluoropropane) and mixtures thereof.
  • the pharmaceutical composition is formed into a dosage form suitable for intranasal, oral, intravenous, intraarterial, peritoneal, transmucosal, or subcutaneous administration.
  • the pharmaceutical composition is formulated as a capsule, a tablet, a liquid, or a syrup.
  • the dosage form is granules or pellets delivered in a sachet or filled into capsule or compressed into a tablet.
  • the pharmaceutical composition further comprises triglycerides, fats, lipids, oils, fatty acids, co-solvents or mixtures thereof.
  • the pharmaceutical composition comprises an edible oil or fat.
  • the pharmaceutical composition comprises an edible oil selected from the group consisting of copaiba oil, coconut oil, cottonseed oil, soybean oil, safflower oil, sesame oil, sunflower oil, castor oil, corn oil, olive oil, palm oil, peanut oil, and poppy seed oil.
  • the pharmaceutical composition comprises copaiba oil.
  • the pharmaceutical composition comprises alcohol and a solvent.
  • the alcohol is ethanol.
  • the solvent is polyethylene glycol (PEG) or propylene glycol.
  • the pharmaceutical further comprises vitamins, minerals, and/or flavoring agents.
  • the pharmaceutical composition is formulated for slow release of the cannabinoid component. According to some embodiments, the pharmaceutical composition is formulated for slow release of the CBDA ester. In certain embodiments, the pharmaceutical composition further comprises a release retarding agent or a mixture of release retarding agents. According to some embodiments, the pharmaceutical composition is at least partly coated by an enteric coating agent.
  • the composition is a gel, wherein the cannabinoid component or acceptable salt thereof is entrapped in a gel matrix.
  • the gel compositions of the present invention may comprise an oil-in water (o/w) emulsion.
  • Bioavailability refers to the extent and rate at which the active moiety (drug or metabolite) enters systemic circulation, thereby accessing the site of action.
  • the bioavailability enhancing agent is an edible oil or fat, a protective colloid, or both a protective colloid and an edible oil or fat.
  • the bioavailability enhancing agent is also a lipophilic active agent taste masking agent.
  • the bioavailability of the lipophilic active agent in a subject is at least about 2 times, 5 times, or 10 times greater than the bioavailability of the lipophilic active agent in the subject in the absence of the bioavailability enhancing agent.
  • the cannabinoid component provided in microencapsulation particles may be provided in microencapsulation particles.
  • the CBDA ester provided in microencapsulation particles may result in cannabinoids and other materials present in cannabinoid materials in liposomal capsule particles or other types of particles.
  • Microencapsulation or nanoencapsulation may increase cannabinoid bioavailability, thereby increasing cannabinoid efficacy after absorption through the mucosal membrane.
  • Microencapsulation or nanoencapsulation may result in particles of 20-40 nm in size.
  • Microencapsulation or nanoencapsulation promotes dissolution of cannabinoid particles in an aqueous environment.
  • the pharmaceutical composition comprises at least one micelle-forming compound selected from the group consisting of a polyoxyethylene ether, ester or alcohol; an alkali metal alkyl sulfate; a bile acid; lecithin, hyaluronic acid, pharmaceutically acceptable salts of hyaluronic acid, octylphenoxypolyethoxyethanol, glycolic acid, lactic acid, chamomile extract, cucumber extract, oleic acid, linolenic acid, borage oil, evening of primrose oil, trihydroxy oxo-cholanylglycine, glycerin, poly glycerin, lysine, polylysine, triolein, salts thereof, and mixtures thereof.
  • a micelle-forming compound selected from the group consisting of a polyoxyethylene ether, ester or alcohol; an alkali metal alkyl sulfate; a bile acid; lecithin, hyaluronic acid, pharmaceutically acceptable salts
  • the bile acids or bile acid salts are selected from the group consisting of chenodesoxycholic acid (CDCA), desoxy cholic acid (DC A), lithocholic acid (LCA), taurodesoxy cholic acid (TDCA), hyodeoxycholic acid (HDCA), taurocholic acid (TCA), glycocholic acid (GCA), and combinations thereof.
  • the pharmaceutical composition comprises phospholipids.
  • the pharmaceutical composition comprises a phospholipid selected from the group consisting of naturally occurring phospholipids and synthetic phospholipids.
  • the naturally occurring phospholipid is selected from the group consisting of soy lecithin, egg lecithin, hydrogenated soy lecithin, hydrogenated egg lecithin, and a combination thereof.
  • the synthetic phospholipid is selected from the group consisting of phosphocholines, phosphoethanolamines, phosphatidic acids, phosphoglycerols, phosphoserines, mixed chain phospholipids, lysophospholipids, pegylated phospholipids, and a combination thereof. Each possibility represents a separate embodiment of the invention.
  • the phospholipid may form micelles, emulsions or liposomes.
  • the present pharmaceutical composition is in the form of an emulsion, which includes the phospholipid as an emulsifying agent.
  • the present pharmaceutical composition is in the form of a micelle, which includes the phospholipid as a micelle forming agent.
  • the present pharmaceutical composition is in the form of a liposomal composition, which includes the phospholipid as the liposome-forming agent.
  • the pharmaceutical composition comprises cyclodextrins.
  • the cyclodextrin is selected from the group consisting of hydroxypropyl b-cyclodextrin, sulfobutylether b-cyclodextrin, and methyl ⁇ -cyclodextrin (IV ⁇ CD) and a combination thereof.
  • the pharmaceutical composition comprises a pharmaceutically acceptable solvent, i.e. a non-toxic solvent that is suitable for administration to a mammal with no unacceptable adverse effects.
  • a pharmaceutically acceptable solvent i.e. a non-toxic solvent that is suitable for administration to a mammal with no unacceptable adverse effects.
  • the solvent may be an aqueous or non-aqueous solvent.
  • Suitable solvents include alcohol solutions, especially ethanol.
  • the pharmaceutical composition may optionally contain a stabilizer and/or a preservative.
  • Phenolic compounds i.e. compounds comprising one or more hydroxyl groups on a benzyl ring, are particularly suited for this purpose as they not only stabilize the composition, but they also enhance absorption of the composition.
  • Preferred phenolic compounds include phenol, methyl phenol and mixtures thereof.
  • the pharmaceutical composition may also comprise one or more of the following additional additives: inorganic salts, antioxidants, protease inhibitors, colorants and flavoring agents.
  • inorganic salts include sodium, potassium, calcium and zinc salts, especially sodium chloride, potassium chloride, calcium chloride, zinc chloride and sodium bicarbonate.
  • Orally administered formulations such as tablets may optionally be coated and may be formulated so as to provide sustained, delayed or controlled release of the active ingredient therein.
  • sustained refers to a composition which provides prolonged, long or extended release of the therapeutic agent. This term may further refer to a composition which provides prolonged, long or extended duration of action (pharmacokinetics) of a pharmaceutical composition comprising a therapeutically effective amount of the pharmaceutical composition of the present invention.
  • the pharmaceutical composition can include additional ingredients including but not limited to the excipients described herein.
  • one or more therapeutic agents of the dosage unit may exist in an extended or control release formulation and additional therapeutic agents may not exist in extended release formulation.
  • the cannabinoid component ester described herein may exist in a controlled release formulation or extended release formulation in the same dosage unit with another agent that may or may not be in either a controlled release or extended release formulation.
  • the composition further comprises at least one pharmaceutically acceptable excipient.
  • the excipient is selected from the group consisting of emulsifiers, buffering agents, pH adjusting agents, tonicity modifiers, preservatives, antioxidants, stabilizers, and a combination thereof.
  • the pharmaceutically acceptable carrier is an aqueous carrier.
  • the aqueous carrier is a physiologically acceptable buffer having physiological or near-physiological pH.
  • the composition further comprising at least one pharmaceutically acceptable excipient.
  • the excipient is selected from, but not limited to, emulsifiers, buffering agents, pH adjusting agents, tonicity modifiers, preservatives, antioxidants, stabilizers, or any other pharmaceutically acceptable excipient known in the art.
  • the pharmaceutical composition may comprise at least one physiologically acceptable film forming agent such as pullulan, methyl cellulose, ethyl cellulose, sodium carboxymethyl cellulose, hydroxypropylmethyl cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, carboxymethyl cellulose, polyvinyl pyrrolidone, methacrylic acid polymers, methacrylic acid copolymers, acrylic acid polymers, acrylic acid copolymers, polyacrylamides, polyalkylene oxides, carrageenan, polyvinyl alcohol, sodium alginate, polyethylene glycol, polyacrylic acid, glycolide, polylactide, methylmethacrylate copolymer, carboxyvinyl polymer, amylose, high amylose starch, hydroxypropylated high amylose starch, alginic acid, pea starch, dextrin, pectin, chitin, chitosan, levan, elsinan and mixtures thereof.
  • Additional film forming agents may be added to optimize characteristics such as tensile strength, stability, flexibility and brittleness including agents such xanthan gum, tragacanth gum, guar gum, locust bean gum, acacia gum, arabic gum, collagen, gelatin, zein, gluten, soy protein isolate, whey protein isolate, casein and mixtures thereof.
  • the orally administrable formulation comprises a mixture of sodium carboxymethylcellulose and hydroxypropyl- cellulose or methyl cellulose as the film-forming agents.
  • the ratio of sodium carboxymethylcellulose to hydroxypropyl cellulose (or methylcellulose) used to make the formulation is chosen to yield the desired dissolution time and to further impart acceptable product handling characteristics.
  • the composition comprises less than about 10% (w/w) of the cannabinoid component. According to additional embodiments, the composition comprises less than about 7% (w/w) of the cannabinoid component. According to further embodiments, the composition comprises less than about 5% (w/w) of the cannabinoid component. According to yet further embodiments, the composition comprises less than about 2% (w/w) of the cannabinoid component. According to some embodiments, the composition comprises less than about 1% (w/w) of the cannabinoid component. According to additional embodiments, the composition comprises less than about 0.5% (w/w) of the cannabinoid component.
  • the w/w unit is intended to refer to the relative weight amount of the cannabinoid component within the composition. For example, if the total weight of the composition is 1 gram and the weight of the cannabinoid component therein is 50 milligrams, the composition is said to comprise 5% (w/w) of the cannabinoid component.
  • the pharmaceutical composition is in a solid or semisolid form.
  • smokeolid refers to a form which on one hand supports its own weight and holds its shape and on the other hand is capable of conforming in shape in response to external pressure.
  • the invention also provides a pharmaceutical pack or kit comprising one or more containers filled with one or more of the pharmaceutical compositions of the invention.
  • the amount of any active agent that is administered to a patient to treat that patient will be administered in a therapeutically effective amount, as determined by ordinarily skilled physicians, pharmacologists, and toxicologists, that take into account the weight and age of the patient.
  • a therapeutically effective amount of the cannabinoid component is an amount approved by the regulatory authority.
  • the pharmaceutical composition further comprises an additional therapeutic agent.
  • the additional therapeutic agent is corticosteroids.
  • Suitable corticosteroids include budesonide, fluticasone, fhmisolide, triamcinolone, beclomethasone, mometasone, ciclesonide, dexamethasone, and the like.
  • the pharmaceutical composition further comprises an anti-asthma molecule.
  • Anti-asthma molecules include but not limited to AVE0547 (anti-inflammatory, Sanofi-Aventis), AVE0675 (TLR agonist, Pfizer, Sanofi-Aventis), AVE5883 (NK1/NK2 antagonist, Sanofi-Aventis), AVE8923 (tryptase beta inhibitor, Sanofi-Aventis), CGS21680 (adenosine A2A receptor agonist, Novartis AG), ATL844 (A2B receptor antagonist, Novartis AG), BAY443428 (tryptase inhibitor, Bayer AG), CHF5407 (M3 receptor inhibitor, Chiesi Farmaceutici S.p.A.), CPLA2 Inhibitor Wyeth, IMA-638 (Anrukinzumab; IL-13 antagonist, Wyeth), LAS 100977 (LAB A, Laboratorios Almirall, S.A.), M
  • the pharmaceutical composition further comprises an antibiotic, such as a macrolide (e.g., azithromycin, clarithromycin and erythromycin), a tetracycline (e.g., doxycycline, tigecycline), a fluoroquinolone (e.g., gemifloxacin, levofloxacin, ciprofloxacin and moxifloxacin), a cephalosporin (e.g., ceftriaxone, cefotaxime, ceftazidime, cefepime), a penicillin (e.g., amoxicillin, amoxicillin with clavulanate, ampicillin, piperacillin, and ticarcillin) optionally with a b-lactamase inhibitor (e.g., sulbactam, tazobactam and clavulanic acid), such as ampicillin-sulbactam, piperacillin-tazobactam and ticarcill
  • an antibiotic such
  • a monobactam e.g., aztreonam
  • an oxazolidinone e.g., linezolid
  • vancomycin glycopeptide antibiotics (e.g. telavancin)
  • tuberculosis-mycobacterium antibiotics tobramycin, azithromycin, ciprofloxacin, colistin, and the like.
  • compositions of the present invention may be formulated for an inhalation as known in the art.
  • CBDA-ME is prepared in some embodiments as an inhalable dry powder or as an aerosol solution.
  • Dry powder formulations for inhalation therapy are described, e.g., in U.S. Pat. No. 10,588,870 to Lipp and Sung; U.S. Pat. No. 5,993,805 to Sutton et al.; U.S. Pat. No. 6,921,527 to Platz et ah; WO 1999016419 to Tarara et al.; and WO 2000000215 to Bot et al.
  • compositions of the present invention may be formulated as single-phase aqueous, emulsion or multiple emulsions.
  • the composition is formulated as emulsion.
  • emulsions may be oil-in-water (o/w) (including silicone in water) emulsions, water-in-oil (including water-in-silicone) (w/o) emulsions, or multiple emulsions such as oil-in-water-in-oil (o/w/o) or water-in-oil-in- water (w/o/w).
  • the oil phase can comprise silicone oils, non silicone organic oils, or mixtures thereof.
  • the compositions can comprise two immiscible phases that are admixed at the time of use by shaking. Each possibility represents a separate embodiment of the present invention.
  • the composition is made by preparing a dispersion of each component in a suitable solvent (dispersant), adjusting the dispersion pH with a pH adjusting agent, if necessary, and admixing the dispersions with shear to permit the formation of the desired matrix.
  • a common mode of administration of medical cannabis is by dissolving the cannabis extract or pure cannabinoid in triglyceride oils, such as vegetable oils, for oral delivery.
  • the oil is either filled into capsules or used as-is in various volumes.
  • the oral route of drug administration is most convenient to most people, and is perceived as an acceptable mode of self-medication, such as consuming a pill.
  • an immediate release of the cannabinoids is obtained with fast absorption and an intermediate duration time of activity, but longer than smoking or vaporizing.
  • a major drawback of dissolving cannabinoids in triglyceride oils is the inability to reach high concentrations of cannabinoids in a single unit dose, due to the limited solubility of cannabinoids and specifically cannabidiol in vegetable oils. Therefore, many products are “cannabis oils” which are cannabinoids dissolved in a vegetable oil and administered in relatively large volumes. However, a limitation of this approach is the unfavorable taste and smell, characteristic of the vegetable oils and cannabinoids, which often result in poor patient compliance.
  • Kits containing the above compositions are also contemplated.
  • Compositions of the present invention can be packaged to contain, separately or in kit form together with a container, instructions or instruction brochure.
  • the present invention provides a method for treating or preventing respiratory inflammation or distress including coronavirus and ARDS, comprising administering to a subject in need thereof a therapeutically effective amount of a pharmaceutical composition comprising a cannabinoid component, wherein the cannabinoid component comprises a cannabidiolic acid (CBDA) ester represented by the structure of Formula (I) alone or in combination with one or more additional cannabinoid compound(s), and a pharmaceutically acceptable carrier, excipient or diluent, wherein
  • CBDA cannabidiolic acid
  • Ri and R 2 are each independently selected from the group consisting of a linear or branched, unsubstituted or substituted C 1 -C 15 alkyl, a linear or branched, unsubstituted or substituted C 2 -C 15 alkenyl, and a linear or branched, unsubstituted or substituted C 2 -C 15 alkynyl; and stereoisomers and salts thereof.
  • the present invention provides a method for treating or preventing coronavirus or ARDS, comprising administering to a subject in need thereof a therapeutically effective amount of a pharmaceutical composition comprising a cannabinoid component, wherein the cannabinoid component comprises a cannabidiolic acid (CBDA) ester represented by the structure of Formula (I) alone or in combination with one or more additional cannabinoid compound(s), and a pharmaceutically acceptable carrier, excipient or diluent,
  • CBDA cannabidiolic acid
  • Ri and R 2 are each independently selected from the group consisting of a linear or branched, unsubstituted or substituted C 1 -C 15 alkyl, a linear or branched, unsubstituted or substituted C 2 -C 15 alkenyl, and a linear or branched, unsubstituted or substituted C 2 -C 15 alkynyl; and stereoisomers and salts thereof.
  • the one or more additional cannabinoid compound(s) are present in one or more extracts of a cannabis plant.
  • an effective amount refers to the amount of the agent necessary to elicit the desired biological response.
  • the effective amount of an agent may vary depending on such factors as the desired biological endpoint, the agent to be delivered, the composition of the pharmaceutical composition, the target tissue or cell, and the like.
  • the term "effective amount” refers to an amount sufficient to produce the desired effect, e.g., to reduce or ameliorate the severity, duration, progression, or onset of a disease, disorder, or condition, or one or more symptoms thereof; prevent the advancement of a disease, disorder, or condition, cause the regression of a disease, disorder, or condition; prevent the recurrence, development, onset or progression of a symptom associated with a disease, disorder, or condition, or enhance or improve the prophylactic or therapeutic effect(s) of another therapy.
  • a “therapeutically effective amount” of the CBDA ester refers to an amount that is effective for preventing, ameliorating, or treating the specified disease or disorder.
  • a "therapeutically effective amount" of a combination of the CBDA ester and a second compound refers to an amount of CBDA ester and an amount of the second compound that, in combination, is effective for preventing, ameliorating, or treating the specified disease or disorder.
  • treatment includes but is not limited to, alleviating a symptom of a disease or condition; and/or reducing, suppressing, inhibiting, lessening, or affecting the progression, severity, and/or scope of a disease or condition.
  • the term “subject” designates a mammal, preferably a human.
  • Coronaviruses treated with compositions described herein include veterinary and human coronaviruses.
  • Human coronaviruses to be treated include Human coronavirus 229E (HCoV-229E), Human coronavirus OC43 (HCoV-OC43), Severe acute respiratory syndrome coronavirus (SARS-CoV), Human coronavirus NL63 (HCoV- NL63, New Haven coronavirus), Human coronavirus HKU1, Middle East respiratory syndrome-related coronavirus (MERS-CoV), previously known as novel coronavirus 2012 and HCoV-EMC, and COVID-19 or Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), previously known as 2019-nCoV or "novel coronavirus 2019".
  • HKU1 Middle East respiratory syndrome-related coronavirus
  • SARS-CoV-2 Severe acute respiratory syndrome coronavirus 2
  • 2019-nCoV previously known as 2019-nCoV or "novel coronavirus
  • the method described herein is for used in treating the respiratory inflammation caused by the coronavirus.
  • the pharmaceutical composition described herein is for use in treating respiratory inflammation that caused by other infections or pathologies.
  • inflammation refers to the biological response that occurs in airway conditions caused by either disease or environmental causes. Inflammation is a localized physical condition in which part of the body becomes reddened, swollen, hot, and often painful, especially as a reaction to the airway condition.
  • respiratory inflammation refers to a disease or disorder that one of its symptoms is inflammation in the lungs. Further, the term “respiratory inflammation” refers to any local response in the airway or lungs that is marked by capillary dilatation, leukocytic infiltration, and edema, and that serves as a mechanism initiating the elimination of noxious agents and of damaged tissue.
  • the respiratory inflammation can be associated with a disease or disorder including, but not limited to, asthma, chronic obstructive airway disorder, pneumonia, respiratory syncytial viral infection, bronchitis, bronchiolitis, idiopathic pulmonary fibrosis, cystic fibrosis, acute respiratory distress syndrome, bronchopulmonary dysplasia, occupational respiratory disease, particulate exposure, pleurisy, emphysema, and pulmonary edema.
  • a disease or disorder including, but not limited to, asthma, chronic obstructive airway disorder, pneumonia, respiratory syncytial viral infection, bronchitis, bronchiolitis, idiopathic pulmonary fibrosis, cystic fibrosis, acute respiratory distress syndrome, bronchopulmonary dysplasia, occupational respiratory disease, particulate exposure, pleurisy, emphysema, and pulmonary edema.
  • the respiratory inflammation is acute respiratory inflammation.
  • the respiratory inflammation is chronic respiratory inflammation. According to certain embodiments, the respiratory inflammation is asthma. According to certain embodiments, the respiratory inflammation is COPD.
  • the inflammation is caused by a pathogen.
  • the inflammation is caused by a pathogen selected from the group consisting of bacteria, viruses, or fungi.
  • the inflammation is caused by a virus.
  • the inflammation is caused by Severe acute respiratory syndrome (SARS).
  • the inflammation is caused by COVID-19.
  • the method is for treating respiratory inflammation related disease or disorder.
  • the respiratory inflammation related disease is lung cancer.
  • the pharmaceutical composition is used in combination with other therapeutic agents for treatment or prevention of respiratory inflammation.
  • the method further comprises administering an anti-inflammatory drug.
  • the drug is acemetacin, acetylsalicylic acid (ASA), alclofenac, alminoprofen, azapropazone, benorylate, benoxaprofen, bucloxic acid, carprofen, choline magnesium trisalicylate, clidanac, dapsone, diclofenac, diflunisal, droxicam, etodolac, fenoprofen, fenbufen, fenclofenac, fentiazac, floctafenine, flufenisal, flurbiprofen, (r)-flurbiprofen, (s)-flurbiprofen, furofenac, flufenamic acid, fluprofen, ibufenac, ibuprofen, indometacin, indoprofen,
  • ASA acetyl
  • the treatment reduces inflammatory.
  • the treatment ameliorates the symptoms of the inflammation.
  • the beneficial effect can be evidenced, for example, by a delayed onset of clinical symptoms of the disease or condition in a susceptible subject, a reduction in severity of some or all clinical symptoms of the disease or condition, a slower progression of the disease or condition, a reduction in the number of relapses of the disease or condition, an improvement in the overall health or well-being of the subject, by other parameters well known in the art that are specific to the particular disease or condition, and combinations of such factors.
  • the route of administration can be by any route and will be determined based on the physician and the patient. All other routes of administration of a therapeutically effective amount of an agent to treat a patient having respiratory inflammation are contemplated herein and include, without limitation, enteral (e.g., orally), or parenteral (e.g., intravenous, subcutaneous or by inhalation), or other routes (e.g., intranasal, intradermal, subcutaneous, and transdermal).
  • enteral e.g., orally
  • parenteral e.g., intravenous, subcutaneous or by inhalation
  • other routes e.g., intranasal, intradermal, subcutaneous, and transdermal.
  • the pharmaceutical composition is administered by inhalation. According to certain embodiments, the pharmaceutical composition is administered intranasally. According to other embodiments, the pharmaceutical composition is administered orally.
  • the pharmaceutical composition is administered once a day, twice a week, once a week, once in two weeks, once in three weeks or once a month. According to yet further embodiments, the composition is administered once in two months, once in three months, once in four months, once in five months or once in six months.
  • the pharmaceutical composition is administered for a period of greater than a week. According to some embodiments, the pharmaceutical composition is administered for a period of greater than four weeks. According to some embodiments, the pharmaceutical composition is administered for a period of greater than two months. According to some embodiments, the pharmaceutical composition is administered for a period of greater than 3, 4, 5, or 6 months.
  • the effective dose of the cannabinoid component ranges from 0.1 to 500 mg/kg/day of body weight, from 1 to 250 mg/kg/day of body weight, from 2 to 100 mg/kg/day of body weight, or from 5 to 30 mg/kg/day, and may be in single dose or divided throughout the day.
  • Each possibility represents a separate embodiment of the invention.
  • the effective dose of the CBDA ester ranges from 0.1 to 500 mg/kg/day of body weight, from 1 to 250 mg/kg/day of body weight, from 2 to 100 mg/kg/day of body weight, or from 5 to 30 mg/kg/day, and may be in single dose or divided throughout the day.
  • Each possibility represents a separate embodiment of the invention.
  • the effective dose of CBDA-ME ranges from 0.1 to 500 mg/kg/day of body weight, from 1 to 250 mg/kg/day of body weight, from 2 to 100 mg/kg/day of body weight, or from 5 to 30 mg/kg/day, and may be in single dose or divided throughout the day.
  • Each possibility represents a separate embodiment of the invention.
  • the pharmaceutical composition is administered at a unit dosage form of approximately 0.05 g/kg/day to approximately 0.5 g/kg/day.
  • the active agents of the present invention are effective over a wide dosage range.
  • the cannabinoid component dosage is 0.5 mg, 1 mg, 2 mg, 3 mg, 5 mg, 10 mg, 15 mg, 20 mg, 25, mg, 50 mg, 75 mg, 100 mg, 200 mg, 300 mg, 400 mg, 500 mg, or 1000 mg per day orally.
  • the CBDA ester dosage is 0.5 mg, 1 mg, 2 mg, 3 mg, 5 mg, 10 mg, 15 mg, 20 mg, 25, mg, 50 mg, 75 mg, 100 mg, 200 mg, 300 mg, 400 mg, 500 mg, or 1000 mg per day orally.
  • CBDA-ME dosage is 0.5 mg, 1 mg, 2 mg, 3 mg, 5 mg, 10 mg, 15 mg, 20 mg, 25, mg, 50 mg, 75 mg, 100 mg, 200 mg, 300 mg, 400 mg, 500 mg, or 1000 mg per day orally.
  • the unit dosage form is administered with food at any time of the day, without food at any time of the day, with food after an overnight fast (e.g., with breakfast).
  • compositions of the invention may be administered in combination with one or more additional compounds or therapies, the latter using enteral or parenteral and include, but are not limited to, by inhalation, oral, intradermal, intramuscular, intravenous, subcutaneous, intranasal, and transdermal administration routes.
  • CBDA-ME is prepared for inhalation as known in the art, e.g., US patent Nos. 10,588,870 and 10,064,821. Briefly, CBDA-ME oil is weighed and transferred to a suitable container, and ethanol (1:2) is added till solution is observed. The solution is transferred to an appropriate aerosol container and a metered dose inhaler valve is crimped on. The sample is then pressure filled with HFA 134a.
  • a murine model of allergen-induced airway inflammation is used to examine the effects of CBDA-ME on airway inflammation and remodeling.
  • Sensitized BALB/c mice are intraperitoneal injected with ovalbumin (10 pg of OVA in 100 pi saline) every alternate day for two weeks. Then, 20 pg of OVA in 20 m ⁇ saline are instilled intratracheally. The mice are then intranasally or orally administered with 5 or 10 mg/kg CBDA-ME, CBD or saline as control. Following treatment, the mice are examined for airway responsiveness as well as lung mechanics with methacholine challenge. Then, the mice are killed and analyzed for the number of mononuclear cells (MN), and eosinophils in the lung. Lung homogenates are used to measure cytokines in the lungs.
  • MN mononuclear cells
  • Example 5 Efficacy of CBDA-ME compositions in mice model of SARS-CoV
  • CBDA-ME The therapeutic effect of CBDA-ME is examined in mouse models of SARS- CoV, such as described in US2017/0027975.
  • CBDA-ME, CBD, or control are administered to the mice as described in Example 4.
  • the therapeutic effect is evaluated by measuring the inflammatory factors as described in Example 4, as well as the ability of the compounds to protect the mice from weight loss, clinical disease and reduce virus titer.
  • ARDS was induced by LPS: LPS of Escherichia coli serotype 055:B5 is dissolved in sterile PBS at 2 mg/ml. LPS is aliquoted into glass vials and kept frozen. On the day of the experiment the vails are thawed for 1 hr in 25 °C and diluted in sterile PBS to a final concertation of 1 mg/ml. To generate aerosol the PulmoAide (DeVilbiss) vaporizer is used. Aerosol is administered at a pressure of 2.5 bar and a rate of 0.15 ml/min.
  • DeVilbiss PulmoAide
  • mice While receiving the aerosol the mice are kept in a Polypropylene (PP) and Poly cyclohexane 1, 4 Dimethylterephthalate (Tritan) closed lead (5L) cage (22X14X17cm). Aerosol is administered and then removed from the cage using plastic tubing. A liquid trap is connected to the exhaust tubing to capture residual LPS. Groups of 10 mice are placed in the breathing chamber and 8 ml of LPS (1 mg/ml) are added to the Nebulizer cup. After 50 min of nebulization the mice are removed. Before placing a new group of mice, the chamber is cleaned using disposable disinfectant wipes. Control groups received nebulization with 8 ml of sterile PBS only with a clean nebulization chamber and nebulizer.
  • PP Polypropylene
  • Tritan Poly cyclohexane 1, 4 Dimethylterephthalate
  • Aerosol based formulation - CBDA-ME (5, 10 and 20 mg/Kg); CBD (5, 10, and 20 mg/Kg), prednisolone (10, 20, 40mg/Kg) or PBS. The mice are treated once.
  • Lavage is performed using PBS with 100 mM EDTA.
  • a 23 G needle inserted into transparent plastic polyethylene 21 G tubing (inner diameter: 0.58 mm, outer diameter: 0.965 mm, and length: 0.5 cm) is used as the catheter.
  • bronchoalveolar fluid (BALF) removal animals are sacrificed using ketamine and xylazine lethal dose.
  • the Animal is placed on its back on a surgical plate and fixed by pinning down the limbs. After spraying the animal with ethanol, an incision the skin in the neck is made, the muscle and salvia glands is set aside and the trachea is exposed. Once the trachea is exposed, a cotton surgical thread is placed around the trachea. The trachea is then carefully punctured at the middle using a 26 G needle. The catheter is inserted about 0.5 cm into the trachea. Stabilizing the catheter is ensured by tying the trachea around the catheter using the cotton thread placed earlier.
  • Aspiration with PBS-EDTA is performed three times, 700 pi each time.
  • the first aspiration fluid is collected into an Eppendorf test tube.
  • the other two aspiration are collected into a separate tube.
  • the lavage fluid from the first tube is centrifuged for 7 min at 400 x g, 4 °C.
  • the supernatant from this tube is collected for ELISA testing and frozen in -80.
  • the cell pellet is suspended with the fluids collected in aspiration 2 and 3. From this tube 200 pi is taken to FACS analysis.
  • the remaining fluid is centrifuged 7 min at 400 x g and 4 °C and the cell pellet is taken to RNA extraction using EZ-RNA extraction kit.
  • mice are examined for hematological parameters: Number and differential of leukocytes subsets (macrophages, neutrophils, lymphocytes, monocytes) and cytokines level: TNFa, IL-6, IL-10, IL-12p40, ILlbeta (either by ELISA or by mRNA levels via qPCR).

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention concerne des compositions et des méthodes de traitement de la détresse respiratoire, dont le coronavirus et le syndrome de détresse respiratoire aiguë. En particulier, la présente invention concerne des formulations et des compositions pharmaceutiques comprenant un ester d'acide cannabidiolique (CBDA) seul ou combiné à un ou plusieurs composés cannabinoïdes supplémentaires, et un support, excipient ou diluant pharmaceutiquement acceptable, destinées à être utilisées dans le traitement du syndrome de détresse respiratoire aiguë.
PCT/IL2021/050518 2020-05-07 2021-05-06 Esters d'acide cannabidiolique pour le traitement de la détresse respiratoire, dont le syndrome de détresse respiratoire aiguë et le coronavirus Ceased WO2021224924A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063021135P 2020-05-07 2020-05-07
US63/021,135 2020-05-07

Publications (1)

Publication Number Publication Date
WO2021224924A1 true WO2021224924A1 (fr) 2021-11-11

Family

ID=78467890

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IL2021/050518 Ceased WO2021224924A1 (fr) 2020-05-07 2021-05-06 Esters d'acide cannabidiolique pour le traitement de la détresse respiratoire, dont le syndrome de détresse respiratoire aiguë et le coronavirus

Country Status (1)

Country Link
WO (1) WO2021224924A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022094330A3 (fr) * 2020-10-29 2022-07-21 Nagy Aurangzeb Nafees Compositions et méthodes de traitement d'insuffisance respiratoire aiguë et/ou de syndrome de détresse respiratoire aiguë à l'aide de tétrahydrocannabinol et compositions le comprenant
US20230338396A1 (en) * 2020-05-14 2023-10-26 Augusta University Research Institute, Inc. Cannabidiol as a therapeutic modality for covid-19

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BYRAREDDY SN ET AL.: "SARS-CoV2 induced respiratory distress: Can cannabinoids be added to anti-viral therapies to reduce lung inflammation?", BRAIN, BEHAVIOR, AND IMMUNITY, vol. 87, 28 April 2020 (2020-04-28), pages 120 - 121, XP086197997, DOI: 10.1016/j.bbi.2020.04.079 *
NICHOLS JM ET AL.: "Immune responses regulated by cannabidiol", CANNABIS AND CANNABINOID RESEARCH, vol. 5, no. 1, 27 February 2020 (2020-02-27), XP055872010, Retrieved from the Internet <URL:https://doi.org/10.1089/can.2018.0073> *
ROH GS ET AL.: "Anti-inflammatory effects of celecoxib in rat lungs with smoke-induced emphysema", AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY, vol. 299, no. 2, 31 August 2010 (2010-08-31), pages L184 - 91, XP055872008 *
TAKEDA S ET AL.: "Cannabidiolic acid as a selective cyclooxygenase-2 inhibitory component in cannabis", DRUG METABOLISM AND DISPOSITION, vol. 36, no. 9, 1 September 2008 (2008-09-01), pages 1917 - 21 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230338396A1 (en) * 2020-05-14 2023-10-26 Augusta University Research Institute, Inc. Cannabidiol as a therapeutic modality for covid-19
WO2022094330A3 (fr) * 2020-10-29 2022-07-21 Nagy Aurangzeb Nafees Compositions et méthodes de traitement d'insuffisance respiratoire aiguë et/ou de syndrome de détresse respiratoire aiguë à l'aide de tétrahydrocannabinol et compositions le comprenant

Similar Documents

Publication Publication Date Title
CN101959429B (zh) 抗微生物肽系统的激动剂
WO2021206877A1 (fr) Inhibiteurs de la réplication de norovirus et de coronavirus
TW202023623A (zh) 孟魯司特與肽的新共軛物
WO2007095041A2 (fr) Formulations pharmaceutiques
EP4125802B1 (fr) 5-amino-2,3-dihydro-1,4-phtalazinedione pour le traitement d&#39;une lésion pulmonaire aiguë
WO2007095043A2 (fr) Formulations pharmaceutiques
KR101005819B1 (ko) 데히드로에피안드로스테론의 네뷸라이저 제제 및 이의조성물을 사용한 천식 또는 만성 폐색성 폐 질환의 치료방법
EP1981545A2 (fr) Formulations pharmaceutiques
WO2021224924A1 (fr) Esters d&#39;acide cannabidiolique pour le traitement de la détresse respiratoire, dont le syndrome de détresse respiratoire aiguë et le coronavirus
JP2023503380A (ja) ペプチド及び炎症の治療におけるそれらの使用
US20220105082A1 (en) New formulations containing leukotriene receptor antagonists
MXPA06001162A (es) Combinacion de dehidroepiandrosterona o sulfato de dehidroepiandrosterona con un inhibidor de pde-4 para el tratamiento del asma o de la enfermedad pulmonar obstructiva cronica.
WO2012134965A1 (fr) Modulateurs de canaux chlorure et de transporteurs de chlorure pour thérapie dans les maladies des muscles lisses
WO2004032941A1 (fr) Compositions pharmaceutiques contenant de la polydatine ou ses sels et utilisations de ces dernieres
AU2004261294B2 (en) Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an anticholinergic bronchodilator for treatment of asthma or chronic obstructive pulmonary disease
CN112438942A (zh) 包含碱化剂及其协同物的药物组合物及其应用
US20240316073A1 (en) Cannabidiolic acid esters for treating prader-willi syndrome
EP4429651A1 (fr) Procédés de rupture de biofilm
WO2021137224A1 (fr) Esters d&#39;acide cannabidiolique pour le traitement de la dystrophie musculaire
US20050090455A1 (en) Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a lipoxygenase inhibitor for treatment of asthma or chronic obstructive pulmonary disease
MXPA06001148A (es) Combinacion de dehidroepiandrosterona o sulfato de dehidroepiandrosterona con un broncodilatador beta-agonista para el tratamiento del asma o de la enfermedad pulmonar obstructiva cronica.
HK40107023A (zh) 用於治疗普拉德-威利综合征的大麻二醇酸酯
CN117813081A (zh) 用于治疗普拉德-威利综合征的大麻二醇酸酯
US20110209699A1 (en) Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a lipoxygenase inhibitor for treatment of asthma or chronic obstructive pulmonary disease
TW202535906A (zh) 新型短鏈肽及其衍生物

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21800753

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 21800753

Country of ref document: EP

Kind code of ref document: A1